Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology was developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/03/23 | $90,000,000 | Series A |
Invus OrbiMed Advisors  RA Capital Management | undisclosed |
